Cassava Sciences, Inc.
SAVANASDAQHealthcare
$1.32
+$0.03(+2.33%)
Market Cap$63766423
P/E Ratio—
52W High$4.98
52W Low$1.15
Cassava Sciences, Inc. (SAVA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SAVA · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 12, 2026EPS Actual
-$0.26
Est. -$0.30 · +13.5%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 12, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
SAVA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.30 | -$0.26 | +13.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.27 | -$0.22 | +18.5% | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$0.18 | — | — | — | — |
| — Q2 FY2025 | May 8, 2025 | — | -$0.48 | — | — | — | — |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.68 | -$0.57 | +16.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.37 | -$0.58 | +57.7% | — | — | — |
| ▼ Q3 FY2024 | Aug 8, 2024 | -$0.44 | -$1.28 | -190.9% | — | — | — |
| ▼ Q2 FY2024 | May 10, 2024 | -$0.51 | -$1.41 | -176.5% | — | — | — |
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.5%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.27
EPS Surpr.
+18.5%
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 8, 2025
EPS Actual
-$0.48
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.57
EPS Est.
-$0.68
EPS Surpr.
+16.2%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.58
EPS Est.
-$1.37
EPS Surpr.
+57.7%
Revenue
—
Q3 FY2024
Aug 8, 2024Miss
EPS Actual
-$1.28
EPS Est.
-$0.44
EPS Surpr.
-190.9%
Revenue
—
Q2 FY2024
May 10, 2024Miss
EPS Actual
-$1.41
EPS Est.
-$0.51
EPS Surpr.
-176.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q2 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q1 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q4 FY2025 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2025 | $-0.27 | $-0.27 | $-0.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 12, 2026 | +13.5% | $2.09 | $1.95 | -6.70% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +18.5% | $3.11 | $3.26 | +4.82% |
| — Q3 FY2025 | Aug 14, 2025 | — | $2.28 | $2.41 | +5.70% |
| — Q2 FY2025 | May 8, 2025 | — | $1.56 | $1.70 | +8.97% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +16.2% | $2.40 | $2.48 | +3.33% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +57.7% | $3.80 | $3.62 | -4.74% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -190.9% | $4.31 | $3.72 | -13.69% |
| ▼ Q2 FY2024 | May 10, 2024 | -176.5% | $3.02 | $2.89 | -4.30% |
Q1 FY2026-6.70%
Report Date
Mar 12, 2026
EPS Beat/Miss
+13.5%
Price Before
$2.09
Price After
$1.95
Q4 FY2025+4.82%
Report Date
Nov 12, 2025
EPS Beat/Miss
+18.5%
Price Before
$3.11
Price After
$3.26
Q3 FY2025+5.70%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$2.28
Price After
$2.41
Q2 FY2025+8.97%
Report Date
May 8, 2025
EPS Beat/Miss
—
Price Before
$1.56
Price After
$1.70
Q1 FY2025+3.33%
Report Date
Mar 3, 2025
EPS Beat/Miss
+16.2%
Price Before
$2.40
Price After
$2.48
Q4 FY2024-4.74%
Report Date
Nov 7, 2024
EPS Beat/Miss
+57.7%
Price Before
$3.80
Price After
$3.62
Q3 FY2024-13.69%
Report Date
Aug 8, 2024
EPS Beat/Miss
-190.9%
Price Before
$4.31
Price After
$3.72
Q2 FY2024-4.30%
Report Date
May 10, 2024
EPS Beat/Miss
-176.5%
Price Before
$3.02
Price After
$2.89
Avg Beat Reaction-0.82%
Avg Miss Reaction-8.99%
Beat Rate4 / 8 quarters
Largest Move-13.69% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SAVA ends December
Cassava Sciences, Inc. (SAVA) most recently reported earnings on March 12, 2026 for Q1 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.30 by +13.5%. SAVA has beaten EPS estimates for 4 consecutive quarters. The next SAVA earnings date is expected around September 1, 2026.
Each quarter, investors track SAVA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SAVA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SAVA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SAVA earnings · 5 questionsCassava Sciences, Inc.'s next earnings report is expected around September 1, 2026. SAVA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SAVA historically reports after market close (AMC).
SAVA earnings datewhen is SAVA earningsSAVA next earnings datewhen does SAVA report earningsSAVA earnings calendar
▸ Source: FMP · Cassava Sciences, Inc. SEC filings · US GAAP · Cassava Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026